|Post IPO Valuation|
|POST IPO FUNDING TOTAL||$27M|
|Post IPO Equity, 3/2014 ||$27M|
Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics’ headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.
Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.